Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 25, 2015 2:18 PM ET

Biotechnology

Company Overview of Celgene Cellular Therapeutics

Company Overview

Celgene Cellular Therapeutics engages in the research, recovery culture-expansion, preservation, development, and distribution of placental cells. The company develops placental cells, including stem and progenitor cells as therapeutic agents. It discovers and develops therapeutics from cells derived from the human placenta, as well as from the umbilical cord. The company develops stem cells for therapeutic applications in cancer, as well as autoimmune, cardiovascular, neurological, and degenerative diseases. It also operates a private umbilical cord blood bank. The company was formerly known as Anthrogenesis Corp. and changed its name to Celgene Cellular Therapeutics in 2002. Celgene Cellul...

7 Powder Horn Drive

Warren, NJ 07059-5190

United States

Phone:

908-673-9000

Fax:

908-673-9001

Key Executives for Celgene Cellular Therapeutics

Chief Executive Officer, President and Director
Age: 55
Compensation as of Fiscal Year 2014.

Celgene Cellular Therapeutics Key Developments

Alliqua Amends Licensing Agreement with Celgene Cellular Therapeutics to Market Biovance

Alliqua announced that it has amended a licensing agreement with Celgene Cellular Therapeutics, giving Aliqua the right to market advanced wound care product Biovance for podiatric and orthopedic applications. Biovance is a drug used to manage non-infected wounds including chronic and acute diabetic, pressure, venous and chronic vascular ulcers, and surgical and trauma woulds such as abrasions, lacerations and second-degree burns. Podiatrists use Biovance for sports medicine purposes.

Celgene Cellular Therapeutics Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-08-2014 07:30 AM

Celgene Cellular Therapeutics Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-08-2014 07:30 AM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Stewart Abbot, Ph.D., Executive Director, Integrative Research.

Celgene Cellular Therapeutics Presents at Alliance for Regenerative Medicine 2nd Annual Regen Med Investor Day, Mar-26-2014

Celgene Cellular Therapeutics Presents at Alliance for Regenerative Medicine 2nd Annual Regen Med Investor Day, Mar-26-2014. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Presentation Date & Speakers: Mar-26-2014, Gregory Russotti, Vice President, Technical Operations, Perry Karsen, CEO.

Similar Private Companies By Industry

Company Name Region
Axerion Therapeutics, Inc. United States
Biodesign International, Inc. United States
BioAgra, LLC United States
CompuVax, Inc. United States
NanoBioMagnetics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 11, 2014
Human Longevity, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celgene Cellular Therapeutics, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.